$AGIO
AGIOS PHARMACEUTICALS, INC. Stock $agio

$agio Overview Financials Valuation SEC Filings Company Website

2017 Q3 Form 10-Q Financial Statement

#000143922217000007 Filed on August 08, 2017

Income Statement

Concept	2017 Q3	2017 Q2	2016 Q2
Revenue	$11.36M	$11.35M	$6.978M
YoY Change	26.41%	62.6%	-47.21%
Cost Of Revenue	$0.00
YoY Change
Gross Profit	$11.36M
YoY Change
Gross Profit Margin	100.0%
Selling, General & Admin	$17.46M	$16.13M	$12.64M
YoY Change	47.34%	27.61%	41.55%
% of Gross Profit	153.72%
Research & Development	$72.92M	$79.82M	$50.80M
YoY Change	20.24%	57.11%	39.48%
% of Gross Profit	641.99%
Depreciation & Amortization	$1.600M	$1.600M	$1.400M
YoY Change	14.29%	14.29%	75.0%
% of Gross Profit	14.09%
Operating Expenses	$90.38M	$95.95M	$63.45M
YoY Change	24.66%	51.22%	39.9%
Operating Profit	-$79.02M	-$84.60M	-$56.47M
YoY Change	24.41%	49.81%	75.74%
Interest Expense	$1.880M	$1.520M	$520.0K
YoY Change	176.47%	192.31%	116.67%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$77.14M	-$83.08M	-$55.95M
YoY Change	22.78%	48.49%	75.39%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$77.14M	-$83.08M	-$55.95M
YoY Change	22.76%	48.49%	75.42%
Net Earnings / Revenue	-679.14%	-732.26%	-801.85%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.592M	-$1.777M	-$1.474M
COMMON SHARES
Basic Shares Outstanding	48.39M shares	48.20M shares	37.92M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q3	2017 Q2	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$507.9M	$586.0M	$465.4M
YoY Change	-12.29%	25.92%	25.85%
Cash & Equivalents	$132.7M	$138.7M	$234.0M
Short-Term Investments	$375.2M	$447.3M	$231.3M
Other Short-Term Assets	$15.30M	$13.00M	$8.900M
YoY Change	48.54%	46.07%	93.48%
Inventory
Prepaid Expenses
Receivables	$700.0K
Other Receivables	$4.400M
Total Short-Term Assets	$528.3M	$604.7M	$484.2M
YoY Change	-12.09%	24.89%	24.09%
LONG-TERM ASSETS
Property, Plant & Equipment	$24.02M	$24.77M	$25.13M
YoY Change	-8.54%	-1.44%	30.04%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$133.8M	$129.9M	$46.90M
YoY Change	207.59%	176.97%	-26.95%
Other Assets	$1.070M	$1.249M	$1.382M
YoY Change	-20.09%	-9.62%	109.39%
Total Long-Term Assets	$158.9M	$155.9M	$73.44M
YoY Change	123.48%	112.3%	-12.81%
TOTAL ASSETS
Total Short-Term Assets	$528.3M	$604.7M	$484.2M
Total Long-Term Assets	$158.9M	$155.9M	$73.44M
Total Assets	$687.2M	$760.6M	$557.6M
YoY Change	2.26%	36.41%	17.54%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$17.90M	$23.41M	$18.45M
YoY Change	16.05%	26.89%	106.96%
Accrued Expenses	$30.76M	$29.64M	$14.41M
YoY Change	34.86%	105.64%	24.43%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$88.11M	$93.65M	$67.26M
YoY Change	12.96%	39.22%	48.82%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$149.3M	$158.0M	$201.3M
YoY Change	-22.48%	-21.51%	705.2%
Total Long-Term Liabilities	$149.3M	$158.0M	$201.3M
YoY Change	-22.48%	-21.51%	705.2%
TOTAL LIABILITIES
Total Short-Term Liabilities	$88.11M	$93.65M	$67.26M
Total Long-Term Liabilities	$149.3M	$158.0M	$201.3M
Total Liabilities	$237.4M	$251.6M	$268.5M
YoY Change	-12.27%	-6.29%	282.48%
SHAREHOLDERS EQUITY
Retained Earnings	-$709.8M	-$632.6M	-$363.8M
YoY Change	66.35%	73.88%	78.52%
Common Stock	$1.160B	$1.142B	$652.6M
YoY Change	40.09%	75.03%	7.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$449.8M	$509.0M	$289.1M
YoY Change
Total Liabilities & Shareholders Equity	$687.2M	$760.6M	$557.6M
YoY Change	2.26%	36.41%	17.54%

Cashflow Statement

Concept	2017 Q3	2017 Q2	2016 Q2
OPERATING ACTIVITIES
Net Income	-$77.14M	-$83.08M	-$55.95M
YoY Change	22.76%	48.49%	75.42%
Depreciation, Depletion And Amortization	$1.600M	$1.600M	$1.400M
YoY Change	14.29%	14.29%	75.0%
Cash From Operating Activities	-$77.70M	-$59.00M	$157.8M
YoY Change	58.57%	-137.39%	3845.0%
INVESTING ACTIVITIES
Capital Expenditures	-$2.000M	-$1.000M	-$2.800M
YoY Change	-41.18%	-64.29%	-74.31%
Acquisitions
YoY Change
Other Investing Activities	$68.40M	-$274.6M	$38.50M
YoY Change	-215.35%	-813.25%	-10.67%
Cash From Investing Activities	$66.40M	-$275.8M	$35.70M
YoY Change	-205.9%	-872.55%	10.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$270.2M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.300M	273.2M	1.500M
YoY Change	-96.75%	18113.33%	36.36%
NET CHANGE
Cash From Operating Activities	-77.70M	-59.00M	157.8M
Cash From Investing Activities	66.40M	-275.8M	35.70M
Cash From Financing Activities	5.300M	273.2M	1.500M
Net Change In Cash	-6.000M	-61.60M	195.0M
YoY Change	-111.65%	-131.59%	422.79%
FREE CASH FLOW
Cash From Operating Activities	-$77.70M	-$59.00M	$157.8M
Capital Expenditures	-$2.000M	-$1.000M	-$2.800M
Free Cash Flow	-$75.70M	-$58.00M	$160.6M
YoY Change	66.01%	-136.11%	977.85%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Depreciation Depreciation	3164000	USD
CY2016Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	3428000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	6845000	USD
CY2016Q4	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	335400000	USD
CY2017Q2	us-gaap	Available For Sale Securities Continuous Unrealized Loss Position Fair Value AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue	482700000	USD
CY2017Q2	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	779000	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17106000	USD
CY2017Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	23409000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-330000	USD
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-94000	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	413123000	USD
CY2017Q2	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	577874000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	32002000	USD
CY2017Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	29641000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	476000	USD
CY2017Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2370000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-313000	USD
CY2017Q2	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-650000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	842013000	USD
CY2017Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1142233000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5465406	shares
CY2017Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6203800	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6203800	shares
CY2016Q4	agio	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	20266000	USD
CY2017Q2	agio	Accrued Research And Development Costs Current AccruedResearchAndDevelopmentCostsCurrent	17714000	USD
CY2017Q2	agio	Available For Sale Securities Non Current Minimum Liquidating Period AvailableForSaleSecuritiesNonCurrentMinimumLiquidatingPeriod	P12M
CY2017Q2	agio	Portion Of Potential Milestone Payment Receivable For Specified Regulatory Milestone Events Program PortionOfPotentialMilestonePaymentReceivableForSpecifiedRegulatoryMilestoneEventsProgram	70000000	USD
	agio	Proceeds From Stock Options Exercised In Other Current Assets ProceedsFromStockOptionsExercisedInOtherCurrentAssets	23000	USD
	agio	Proceeds From Stock Options Exercised In Other Current Assets ProceedsFromStockOptionsExercisedInOtherCurrentAssets	3000	USD
	agio	Public Offering Costs In Other Current Assets PublicOfferingCostsInOtherCurrentAssets	0	USD
	agio	Public Offering Costs In Other Current Assets PublicOfferingCostsInOtherCurrentAssets	125000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001439222
CY2017Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48391194	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	AGIOS PHARMACEUTICALS INC
CY2016Q4	us-gaap	Assets Assets	619094000	USD
CY2017Q2	us-gaap	Assets Assets	760600000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	559892000	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	604681000	USD
CY2016Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	13000	USD
CY2017Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	21000	USD
CY2016Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10996000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20103000	USD
	dei	Trading Symbol TradingSymbol	AGIO
CY2017Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12187000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22921000	USD
CY2016Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5465406	shares
CY2016Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	326000	USD
CY2017Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	671000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	412810000	USD
CY2017Q2	us-gaap	Available For Sale Securities AvailableForSaleSecurities	577224000	USD
CY2016Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	380560000	USD
CY2017Q2	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	447325000	USD
CY2016Q4	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	32250000	USD
CY2017Q2	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	129899000	USD
CY2016Q4	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear	158	Securities
CY2017Q2	us-gaap	Availableforsale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Greater Than Or Equal To One Year AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsGreaterThanOrEqualToOneYear	255	Securities
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1360000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1383000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	71764000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	234048000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	160754000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	138717000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	162284000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-22037000	USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	125000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42220444	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48346297	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	42220444	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48346297	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	42000	USD
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	48000	USD
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-55745000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-78536000	USD
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-83520000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-149585000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	3412000	USD
CY2017Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	3529000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	17773000	USD
CY2017Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	16003000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	35913000	USD
CY2017Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	37069000	USD
CY2016Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	154297000	USD
CY2017Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	141957000	USD
	us-gaap	Depreciation Depreciation	2550000	USD
CY2016Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	4886000	USD
CY2017Q2	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	4842000	USD
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.78
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-3.35
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	11092000	USD
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.47
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.09
CY2017Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	8721000	USD
CY2017Q2	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	1000000	USD
CY2017Q2	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2017Q2	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0	USD
CY2017Q2	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-40000	USD
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12644000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	23481000	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16130000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30953000	USD
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-1360000	USD
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-2638000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3755000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4930000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-833000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2392000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	-813000	USD
	us-gaap	Increase Decrease In Deferred Charges IncreaseDecreaseInDeferredCharges	1653000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	190645000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-11184000	USD
	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-372000	USD
	us-gaap	Increase Decrease In Due From Related Parties Current IncreaseDecreaseInDueFromRelatedPartiesCurrent	-44000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1129000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2417000	USD
CY2016Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	517000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	913000	USD
CY2017Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	1518000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2399000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	260503000	USD
CY2017Q2	us-gaap	Liabilities Liabilities	251608000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	619094000	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	760600000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	88433000	USD
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	93648000	USD
CY2016Q2	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
CY2017Q2	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2557000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	277199000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	20912000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-166173000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	138815000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-133063000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-55953000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-79151000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-83082000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-149248000	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	63448000	USD
	us-gaap	Operating Expenses OperatingExpenses	118323000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	95946000	USD
	us-gaap	Operating Expenses OperatingExpenses	173501000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-56470000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-80064000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-84600000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-151647000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	168000	USD
CY2017Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	836000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1615000	USD
CY2017Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1249000	USD
CY2016Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
CY2016Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	208000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	615000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-438000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-337000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	-104000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	226289000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	468556000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5267000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1328000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2017Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10264000	USD
CY2017Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	13018000	USD
CY2017Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	270200000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	270250000	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	2557000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	252468000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	303711000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25337000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24771000	USD
CY2016Q2	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	5922000	USD
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	14716000	USD
CY2017Q2	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	2489000	USD
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	5265000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50804000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	94842000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	79816000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	142548000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-483151000	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-632639000	USD
CY2016Q2	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	6978000	USD
	us-gaap	Revenue From Related Parties RevenueFromRelatedParties	13300000	USD
CY2016Q2	us-gaap	Revenues Revenues	6978000	USD
	us-gaap	Revenues Revenues	38259000	USD
CY2017Q2	us-gaap	Revenues Revenues	11346000	USD
	us-gaap	Revenues Revenues	21854000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	20103000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	22921000	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3004850	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	39.10
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	233817	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1357852	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5218880	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6066163	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	46.79
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	47.73
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	6066163	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	47.73
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	20.85
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	72.39
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	50.12
CY2017Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	5808080	shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	276752	shares
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	358591000	USD
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	508992000	USD
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37956383	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	37910233	shares
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	46745760	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	44525478	shares
	us-gaap	Revenue Recognition Multiple Element Arrangements RevenueRecognitionMultipleElementArrangements	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon the modifications, under the provisions of ASC 605-25, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Multiple Element Arrangements,</font><font style="font-family:inherit;font-size:10pt;"> we identified the remaining deliverables under the modified arrangement, and determined the best estimate of selling price, or BESP, for the undelivered elements as of the modification date. We then allocated the total arrangement consideration, which included the remaining deferred revenue balance at the modification date, any upfront payments received upon modification and other consideration under the modified arrangement that were deemed to be determinable at the modification date, to each unit of accounting relative to our BESP for each unit of accounting. The undelivered elements at the time of the modification, which are each considered by us to have stand-alone value and therefore were determined to be separate units of accounting</font></div></div>

Files In Submission

Name	View Source	Status
0001439222-17-000007-index-headers.html	Edgar Link	pending
0001439222-17-000007-index.html	Edgar Link	pending
0001439222-17-000007.txt	Edgar Link	pending
0001439222-17-000007-xbrl.zip	Edgar Link	pending
agio-0630x17x10q.htm	Edgar Link	pending
agio-20170630.xml	Edgar Link	completed
agio-20170630.xsd	Edgar Link	pending
agio-20170630_cal.xml	Edgar Link	unprocessable
agio-20170630_def.xml	Edgar Link	unprocessable
agio-20170630_lab.xml	Edgar Link	unprocessable
agio-20170630_pre.xml	Edgar Link	unprocessable
exhibit31-1x06x30x2017.htm	Edgar Link	pending
exhibit31-2x06x30x2017.htm	Edgar Link	pending
exhibit32-1x06x30x2017.htm	Edgar Link	pending
exhibit32-2x06x30x2017.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AGIO
AGIOS PHARMACEUTICALS, INC. Stock $agio

2017 Q3 Form 10-Q Financial Statement

#000143922217000007 Filed on August 08, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AGIO AGIOS PHARMACEUTICALS, INC. Stock $agio

2017 Q3 Form 10-Q Financial Statement

#000143922217000007 Filed on August 08, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AGIO
AGIOS PHARMACEUTICALS, INC. Stock $agio